Related Experiment Video
Updated: Jun 3, 2026

13:34
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Target-specific support vector machine scoring in structure-based virtual screening: computational validation, in
Journal of Chemical Information and Modeling
|March 29, 2011
Summary
A new structure-based support vector machine scoring function (SVM-SP) shows superior performance in identifying potential drug compounds, particularly for kinases. This method successfully identified active compounds against EGFR and CaMKII, demonstrating its potential for drug discovery.
Area of Science:
- Computational chemistry and structural biology
- Drug discovery and development
- Bioinformatics and cheminformatics
Background:
- A previously developed structure-based support vector machine target-specific scoring function (SVM-SP) was evaluated across 41 targets.
- The Directory of Useful Decoys (DUD) dataset was utilized for comprehensive performance assessment.
Discussion:
- SVM-SP demonstrated superior enrichment performance compared to Glide and other scoring functions across diverse target families, especially kinases.
- The scoring function exhibited robust performance across different protein classes and even with homology models.
- High enrichment was achieved even with limited training data, indicating efficiency in model building.
Key Insights:
- Virtual screening of 1125 compounds against EGFR and CaMKII identified potent inhibitors.
- Three compounds showed significant in vitro inhibition of EGFR kinase activity and cancer cell proliferation.
- One compound demonstrated dose-dependent inhibition of CaMKII kinase activity.
Outlook:
- The findings suggest SVM-SP's potential for identifying chemical probes for kinases within the human kinome.
- This approach could accelerate drug discovery efforts targeting kinases, which are crucial in chemical biology.
- The success with non-kinase-like binding pockets indicates broader applicability beyond typical kinase inhibitors.

